Santa Ana Bio, a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases, today emerged from stealth with $168 million in combined Series A and B funding. Founding investor Versant Ventures led the Series A round and was joined by TPG's Life Science Innovations fund and GV. The $125 million Series B round was led by GV, with participation from all existing investors as well as new investors Access Biotechnology, Andreessen Horowitz (a16z) Bio + Health and RTW.

Santa Ana Bio is a biotechnology company developing a pipeline of innovative therapeutics and leveraging its multi-omics platform to unlock the full potential of precisions medicines. Santa Ana's platform, based on transcriptomics and proteomics, addresses the limitations of today's commercial therapeutics. The goal is to expand the reach of precision medicines to different cell types and pathways, to benefit more patients with autoimmune and inflammatory diseases.